Targeting a Rare Brain Cancer With Spherical Nucleic Acids
The first drug using spherical nucleic acids to be systemically given to humans has been developed by Northwestern University scientists and approved by the FDA as an investigational drug for clinical investigation in the deadly brain cancer glioblastoma multiforme.
Related coverage:
